Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma

Oncology Practice Insider

On November 14, 2019, the Food and Drug Administration granted accelerated approval to zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Read more